BAX

SEC source: 0001062993-24-011977 · form4.xml · nonDerivative · entry 1

Toth Christopher A. · CIK 0001753950 · EVP,Group Pres, Kidney Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,282

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on June 3, 2024 from the settlement of vested restricted stock units granted on June 1, 2023.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-011976 · form4.xml · nonDerivative · entry 1

Rosenbloom David S. · CIK 0001924321 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,580

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on June 3, 2024 from the settlement of vested restricted stock units granted on June 1, 2022.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009790 · form4.xml · nonDerivative · entry 1

WILVER PETER M · CIK 0001234537 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,267

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009789 · form4.xml · nonDerivative · entry 1

Wilkes David S. · CIK 0001842866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,274

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009787 · form4.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,876

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009786 · form4.xml · nonDerivative · entry 1

Smith Cathy R · CIK 0001322028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,545

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009785 · form4.xml · nonDerivative · entry 1

Shafer David Brent · CIK 0001728374 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,257

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009784 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,278

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009783 · form4.xml · nonDerivative · entry 1

RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,068

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009782 · form4.xml · nonDerivative · entry 1

Oesterle Stephen N. · CIK 0001174532 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,901

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009781 · form4.xml · nonDerivative · entry 1

MORRISON PATRICIA · CIK 0001204081 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,367

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-009779 · form4.xml · nonDerivative · entry 1

Ampofo William A. II · CIK 0001983479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,847

F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-005968 · form4.xml · nonDerivative · entry 1

Toth Christopher A. · CIK 0001753950 · EVP,Group Pres, Kidney Care

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,761

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-005967 · form4.xml · nonDerivative · entry 1

Stevens Brian · CIK 0001557559 · SVP, CAO & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,538

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005966 · form4.xml · nonDerivative · entry 1

Sonig Alok · CIK 0001967368 · EVP,Group President, Pharma

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,454

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005965 · form4.xml · nonDerivative · entry 1

Rosenbloom David S. · CIK 0001924321 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,989

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005963 · form4.xml · nonDerivative · entry 1

Rasul Reazur · CIK 0001967379 · EVP,Group Pres, Healthcare

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,187

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005961 · form4.xml · nonDerivative · entry 1

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,481

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005960 · form4.xml · nonDerivative · entry 1

Borzi James W · CIK 0001495559 · EVP,Chief Supply Chain Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,735

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005959 · form4.xml · nonDerivative · entry 1

Knight Heather · CIK 0001967528 · EVP,Group Pres,Med Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,330

F1 · shares: For 2024, the annual equity grant for the reporting person consisted solely of restricted stock units (RSUs). The reporting person received a grant of RSUs which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005958 · form4.xml · nonDerivative · entry 1

ALMEIDA JOSE E · CIK 0001216761 · Chairman, CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,924

F1 · shares: For 2024, the annual equity grant for the reporting person consisted of 50% restricted stock units (RSUs) and 50% performance share units (PSUs). The PSU grants are subject to potential disclosure at a later date upon the satisfaction of the related performance and time vesting conditions. The amount set forth above represents the grant of RSUs, which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

SEC source: 0001062993-24-005957 · form4.xml · nonDerivative · entry 1

Grade Joel T. · CIK 0001602507 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,623

F1 · shares: For 2024, the annual equity grant for the reporting person consisted of 50% restricted stock units (RSUs) and 50% performance share units (PSUs). The PSU grants are subject to potential disclosure at a later date upon the satisfaction of the related performance and time vesting conditions. The amount set forth above represents the grant of RSUs, which are scheduled to vest in three equal annual installments beginning on March 6, 2025, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. 2021 Incentive Plan.

F2 · balance_after: Total includes the automatic reinvestment of dividends and shares held in the Baxter's Employee Stock Plan.

SEC source: 0001062993-24-005680 · form4.xml · nonDerivative · entry 1

Stevens Brian · CIK 0001557559 · SVP, CAO & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,249

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 4, 2024 from the settlement of vested restricted stock units granted on March 2, 2022 and March 3, 2021.

SEC source: 0001062993-24-005677 · form4.xml · nonDerivative · entry 1

Rasul Reazur · CIK 0001967379 · EVP, Group Pres, Healthcare

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,834

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 4, 2024 from the settlement of vested restricted stock units granted on March 2, 2022 and March 3, 2021.

SEC source: 0001062993-24-005675 · form4.xml · nonDerivative · entry 1

Knight Heather · CIK 0001967528 · EVP,Group Pres, Med Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,162

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 4, 2024 from the settlement of vested restricted stock units granted on March 2, 2022 and March 3, 2021.

SEC source: 0001062993-24-005674 · form4.xml · nonDerivative · entry 1

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,851

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 4, 2024 from the settlement of vested restricted stock units granted on March 2, 2022.

SEC source: 0001062993-24-005673 · form4.xml · nonDerivative · entry 1

Borzi James W · CIK 0001495559 · EVP,Chief Supply Chain Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,394

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 4, 2024 from the settlement of vested restricted stock units granted on March 2, 2022.

SEC source: 0001062993-24-005670 · form4.xml · nonDerivative · entry 1

ALMEIDA JOSE E · CIK 0001216761 · Chairman, CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,033

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 4, 2024 from the settlement of vested restricted stock units granted on March 2, 2022.

SEC source: 0001062993-24-005496 · form4.xml · nonDerivative · entry 1

Stevens Brian · CIK 0001557559 · SVP, CAO & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,795

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

SEC source: 0001062993-24-005495 · form4.xml · nonDerivative · entry 1

Sonig Alok · CIK 0001967368 · EVP, Group President, Pharma

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,101

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-005494 · form4.xml · nonDerivative · entry 1

Rosenbloom David S. · CIK 0001924321 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,405

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

F2 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-005493 · form4.xml · nonDerivative · entry 1

Rasul Reazur · CIK 0001967379 · EVP, Group Pres, Healthcare

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,357

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

SEC source: 0001062993-24-005492 · form4.xml · derivative · entry 4

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $1 par value · 64,488 shares

Expires 2024-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a Rule 10b5-1 trading plan entered into by Ms. Mason on September 6, 2023 with respect to certain vested stock options previously granted by Baxter International Inc. to Ms. Mason which were scheduled to expire on March 4, 2024.

F4 · derivative.exercise_date: The options became exercisable in three equal annual installments beginning on March 4, 2015, the first anniversary of the grant date.

SEC source: 0001062993-24-005492 · form4.xml · nonDerivative · entry 3

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,326

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

SEC source: 0001062993-24-005492 · form4.xml · nonDerivative · entry 2

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,290

F2 · price: Price reflects weighted average sales price. Range of prices for transactions are $40.28 through $40.93. Full information regarding the number of shares sold at each separate price will be provided by Baxter International Inc. upon request.

SEC source: 0001062993-24-005492 · form4.xml · nonDerivative · entry 1

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,778

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction effected pursuant to a Rule 10b5-1 trading plan entered into by Ms. Mason on September 6, 2023 with respect to certain vested stock options previously granted by Baxter International Inc. to Ms. Mason which were scheduled to expire on March 4, 2024.

SEC source: 0001062993-24-005491 · form4.xml · nonDerivative · entry 1

Knight Heather · CIK 0001967528 · EVP, Group Pres, Med Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,483

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

F2 · balance_after: Total includes shares held in the Baxter's Employee Stock Plan.

SEC source: 0001062993-24-005490 · form4.xml · nonDerivative · entry 1

Borzi James W · CIK 0001495559 · EVP, Chief Supply Chain Offcr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,814

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

SEC source: 0001062993-24-005488 · form4.xml · nonDerivative · entry 1

ALMEIDA JOSE E · CIK 0001216761 · Chairman, CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,812

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on March 1, 2024 from the settlement of vested restricted stock units granted on March 1, 2023.

SEC source: 0001062993-24-003182 · form4.xml · nonDerivative · entry 2

Knight Heather · CIK 0001967528 · EVP, Group Pres, Med Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,602

F2 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2021 PSUs.

F3 · balance_after: Totals include the automatic reinvestment of dividends and shares held in the Baxter's Employee Stock Purchase Plan. Totals have been updated to reflect an administrative error that excluded 1,121 shares of common stock that were held by Ms. Knight on the original Form 3 filed on March 3, 2023.

SEC source: 0001062993-24-003182 · form4.xml · nonDerivative · entry 1

Knight Heather · CIK 0001967528 · EVP, Group Pres, Med Products

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,958

F1 · shares: Represents shares awarded from the performance share unit award granted on March 3, 2021 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2021 PSUs). The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2021 to December 31, 2023 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended.

SEC source: 0001062993-24-003180 · form4.xml · nonDerivative · entry 2

Rasul Reaz · CIK 0001967379 · EVP, Group Pres, Healthcare

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,895

F2 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2021 PSUs.

F3 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-003180 · form4.xml · nonDerivative · entry 1

Rasul Reaz · CIK 0001967379 · EVP, Group Pres, Healthcare

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,143

F1 · shares: Represents shares awarded from the performance share unit award granted on March 3, 2021 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2021 PSUs). The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2021 to December 31, 2023 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended.

SEC source: 0001062993-24-003176 · form4.xml · nonDerivative · entry 2

Stevens Brian · CIK 0001557559 · SVP, CAO & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,469

F2 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2021 PSUs.

F3 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-003176 · form4.xml · nonDerivative · entry 1

Stevens Brian · CIK 0001557559 · SVP, CAO & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,753

F1 · shares: Represents shares awarded from the performance share unit award granted on March 3, 2021 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2021 PSUs). The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2021 to December 31, 2023 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended.

SEC source: 0001062993-24-003175 · form4.xml · nonDerivative · entry 2

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,290

F2 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2021 PSUs.

SEC source: 0001062993-24-003175 · form4.xml · nonDerivative · entry 1

Mason Jeanne K · CIK 0001362109 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,753

F1 · shares: Represents shares awarded from the performance share unit award granted on March 3, 2021 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2021 PSUs). The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2021 to December 31, 2023 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended.

SEC source: 0001062993-24-003174 · form4.xml · nonDerivative · entry 2

Borzi James W · CIK 0001495559 · EVP, Chief Supply Chain Office

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,666

F2 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2021 PSUs.

F3 · balance_after: Total includes the automatic reinvestment of dividends.

SEC source: 0001062993-24-003174 · form4.xml · nonDerivative · entry 1

Borzi James W · CIK 0001495559 · EVP, Chief Supply Chain Office

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,977

F1 · shares: Represents shares awarded from the performance share unit award granted on March 3, 2021 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2021 PSUs). The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2021 to December 31, 2023 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended.

SEC source: 0001062993-24-003173 · form4.xml · nonDerivative · entry 2

ALMEIDA JOSE E · CIK 0001216761 · Chairman, CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,513

F2 · shares: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2021 PSUs.

F3 · balance_after: Total includes the automatic reinvestment of dividends.